Evidence map›Paper›PMID 26369985›Full record

ArticleLeukemia2016

Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma.

C J K Lam, R E Curtis, G M Dores, E A Engels, N E Caporaso, A Polliack, J L Warren, H A Young, P H Levine, A F Elmi and 3 more

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Unusual Presentation ofInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

C J K LamDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
R E CurtisDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
G M DoresDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
E A EngelsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
N E CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
A PolliackDepartment of Hematology, Hadassah University Hospital, Jerusalem, Israel.
J L WarrenDivision of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
H A YoungDepartment of Epidemiology and Biostatistics, The George Washington University Milken Institute School of Public Health, Washington, DC, USA.
P H LevineDepartment of Epidemiology and Biostatistics, The George Washington University Milken Institute School of Public Health, Washington, DC, USA.
A F ElmiDepartment of Epidemiology and Biostatistics, The George Washington University Milken Institute School of Public Health, Washington, DC, USA.
J F FraumeniDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
M A TuckerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
L M MortonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
National Cancer Institute · USMilken Institute · USNational Institutes of Health · USHadassah Academic College · IL

Funding

Studies of Populations Exposed to Therapeutic Medical Radiation and Other AgentsZIACP010131 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$81.0M
Infections, immunity, and inflammation in cancerZIACP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2009 to 2025
$24.0M
Multidisciplinary Studies of LymphomaZIACP010170 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$10.7M
Intramural NIH HHS ZIA CP010170
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplasms, Second PrimaryAgedAged, 80 and overAntineoplastic AgentsFemaleHumansLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMaleMultivariate AnalysisMyelodysplastic SyndromesRisk FactorsAntineoplastic Agents

Identifiers

PMID26369985
PMCPMC4792793
OpenAlexW1950494590

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.